Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AARD Aardvark Therapeutics	$10.85 +1.0%	$9.90	$4.88 ▼ $19.58	$235.40M	N/A	95,976 shs	8,065 shs
CRDF Cardiff Oncology	$3.86 +1.3%	$3.04	$2.01 ▼ $5.64	$256.79M	1.61	1.17 million shs	788,839 shs
INZY Inozyme Pharma	$3.97 -0.5%	$2.36	$0.72 ▼ $6.24	$256.31M	2.29	886,450 shs	701,124 shs
ZIVO ZIVO Bioscience	$13.00 -7.1%	$16.41	$5.51 ▼ $22.15	$53.35M	0.02	1,000 shs	630 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AARD Aardvark Therapeutics	0.00%	-9.06%	+8.59%	+15.98%	+1,073,999,900.00%
CRDF Cardiff Oncology	0.00%	-1.80%	+35.59%	-5.93%	+41.11%
INZY Inozyme Pharma	0.00%	0.00%	+1.01%	+291.18%	-15.82%
ZIVO ZIVO Bioscience	0.00%	-18.71%	-22.28%	-21.40%	+75.09%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CRDF Cardiff Oncology	1.8261 of 5 stars	3.5	0.0	0.0	0.0	4.3	0.0	0.6
INZY Inozyme Pharma	3.0404 of 5 stars	4.2	3.0	0.0	0.0	2.0	2.5	0.0
ZIVO ZIVO Bioscience	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AARD Aardvark Therapeutics	3.00	Buy	$31.25	188.02% Upside
CRDF Cardiff Oncology	3.00	Buy	$12.00	210.88% Upside
INZY Inozyme Pharma	2.44	Hold	$11.75	195.97% Upside
ZIVO ZIVO Bioscience	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ZIVO, INZY, CRDF, and AARD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	INZY Inozyme Pharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$4.00
5/16/2025	INZY Inozyme Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$15.00 ➝ $4.00
5/15/2025	AARD Aardvark Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$21.00 ➝ $20.00
5/14/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
5/9/2025	CRDF Cardiff Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$17.00 ➝ $18.00
4/10/2025	INZY Inozyme Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/8/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
4/1/2025	AARD Aardvark Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$21.00 ➝ $21.00

(Data available from 6/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
CRDF Cardiff Oncology	$587K	437.46	N/A	N/A	$1.56 per share	2.47
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	$2.27 per share	N/A
ZIVO ZIVO Bioscience	$15.85K	3,127.38	N/A	N/A	($0.81) per share	-16.05

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AARD Aardvark Therapeutics	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
CRDF Cardiff Oncology	-$41.44M	-$0.92	N/A	N/A	N/A	-6,238.17%	-73.97%	-60.40%	8/14/2025 (Estimated)
INZY Inozyme Pharma	-$71.17M	-$1.69	N/A	N/A	N/A	N/A	-88.42%	-57.02%	8/5/2025 (Estimated)
ZIVO ZIVO Bioscience	-$7.78M	-$4.93	N/A	∞	N/A	N/A	N/A	-2,240.92%	8/12/2025 (Estimated)

Latest ZIVO, INZY, CRDF, and AARD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	N/A	AARD Aardvark Therapeutics	-$0.70	-$0.71	-$0.01	-$0.71	N/A	N/A
5/14/2025	Q1 2025	INZY Inozyme Pharma	-$0.43	-$0.44	-$0.01	-$0.44	N/A	N/A
5/8/2025	Q1 2025	CRDF Cardiff Oncology	-$0.19	-$0.20	-$0.01	-$0.20	$0.09 million	$0.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AARD Aardvark Therapeutics	N/A	N/A	N/A	N/A	N/A
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	N/A
ZIVO ZIVO Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AARD Aardvark Therapeutics	N/A	N/A	N/A
CRDF Cardiff Oncology	N/A	4.74	4.74
INZY Inozyme Pharma	0.51	7.68	7.68
ZIVO ZIVO Bioscience	N/A	0.17	0.17

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AARD Aardvark Therapeutics	N/A
CRDF Cardiff Oncology	16.29%
INZY Inozyme Pharma	88.30%
ZIVO ZIVO Bioscience	12.83%

Insider Ownership

Company	Insider Ownership
AARD Aardvark Therapeutics	N/A
CRDF Cardiff Oncology	7.70%
INZY Inozyme Pharma	12.18%
ZIVO ZIVO Bioscience	48.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AARD Aardvark Therapeutics	18	21.70 million	N/A	N/A
CRDF Cardiff Oncology	20	66.53 million	47.15 million	Optionable
INZY Inozyme Pharma	50	64.56 million	57.05 million	Optionable
ZIVO ZIVO Bioscience	10	3.81 million	2.91 million	Not Optionable

ZIVO, INZY, CRDF, and AARD Headlines

Recent News About These Companies

ZIVO Bioscience (NASDAQ:ZIVO) Share Price Crosses Above 50-Day Moving Average - Time to Sell?

June 7, 2025 | marketbeat.com

ZIVO Bioscience (NASDAQ:ZIVO) Shares Cross Below 50-Day Moving Average - Should You Sell?

May 30, 2025 | marketbeat.com

ZIVO Bioscience (NASDAQ:ZIVO) Share Price Crosses Above Fifty Day Moving Average - Here's What Happened

May 17, 2025 | marketbeat.com

University of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

May 7, 2025 | finance.yahoo.com

University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry

May 6, 2025 | businesswire.com

ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry

February 6, 2025 | businesswire.com

Zivo Bioscience issues new shares, raises $1.5 million

January 28, 2025 | msn.com

Tuesday's Insider Activity: Top Buys and Sells in US Stocks Revealed

January 1, 2025 | investing.com

ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza

December 20, 2024 | businesswire.com

ZIVO Stock Earnings: Zivo Bioscience Reported Results for Q4 2023

March 18, 2024 | investorplace.com

Harmony Biosciences Holdings

March 4, 2024 | forbes.com

Regencell Bioscience Holdings Ltd RGC

February 1, 2024 | morningstar.com

ZIVO Bioscience Announces Uplisting to OTCQB Market

January 29, 2024 | finance.yahoo.com

Ideaya Biosciences

January 18, 2024 | forbes.com

Dare Bioscience Inc DARE

January 14, 2024 | morningstar.com

Zivo Bioscience Inc (ZIVO) USD0.001

November 11, 2023 | hl.co.uk

Zivo Bioscience (ZIVO) Price Target Increased by 500.00% to 36.72

November 2, 2023 | msn.com

Zivo Bioscience Inc ZIVO

November 1, 2023 | morningstar.com

ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens

October 30, 2023 | finance.yahoo.com

Zivo Bioscience Announces 1-for-6 Reverse Stock Split To Regain Compliance

October 26, 2023 | markets.businessinsider.com

Zivo Bioscience to effect reverse stock split to regain compliance with Nasdaq rules

October 26, 2023 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ZIVO, INZY, CRDF, and AARD Company Descriptions

Aardvark Therapeutics NASDAQ:AARD

$10.85 +0.11 (+1.02%)

As of 04:00 PM Eastern

Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.

Cardiff Oncology NASDAQ:CRDF

$3.86 +0.05 (+1.31%)

Closing price 04:00 PM Eastern

Extended Trading

$3.92 +0.06 (+1.42%)

As of 07:26 PM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Inozyme Pharma NASDAQ:INZY

$3.97 -0.02 (-0.50%)

Closing price 04:00 PM Eastern

Extended Trading

$3.98 +0.00 (+0.13%)

As of 04:04 PM Eastern

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

ZIVO Bioscience NASDAQ:ZIVO

$13.00 -0.99 (-7.08%)

As of 02:09 PM Eastern

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time